OncLive TV

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the toxicities associated with chimeric antigen receptor (CAR) T-cell therapy.

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses sacituzumab govitecan (IMMU-132) for the treatment of patients with triple-negative breast cancer.

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing clinical trials and recent approvals that will shape the standard of care in the treatment of patients with neuroendocrine tumors (NETs).

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the role of tucatinib (ONT-380) for patients with HER2-positive breast cancer.

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses advancements with androgen receptor (AR)-directed therapy for patients with prostate cancer.

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center, discusses the findings from a study on the incidence and survival impact of self-reported symptom and psychological distress for patients with multiple myeloma.

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the potential approval of cabozantinib (Cabometyx) in hepatocellular carcinoma (HCC) could affect the treatment landscape in liver cancer.

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses response to the chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with multiple myeloma.

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, on considerations for the treatment of patients with HER2-positive breast cancer.

Samir Taneja, MD, James M. Neissa and Janet Riha Neissa professor of urologic oncology, vice chair, Department of Urology, professor, Department of Radiology, co-director, Smilow Comprehensive Prostate Cancer Center, director, Urologic Oncology, Genito-Urologic program leader, NYU Langone’s Perlmutter Cancer Center, discusses multiparametric MRI in prostate cancer.

Malcolm Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses how to determine a treatment strategy for patients with prostate cancer following the 10-year PROTECT study data.

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the benefits of ibrutinib (Imbruvica) in combination with venetoclax (Venclexta) and obinutuzumab (Gazyva) for patients with chronic lymphocytic leukemia (CLL).

Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discuss the efficacy of selinexor in combination with dexamethasone for the treatment of patients with multiple myeloma.

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of molecular markers in lung cancer.

Alicia Morgan, MD, Mather Hospital, discusses the impact of PARP inhibitors in prostate cancer.

Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses the future of immunotherapy in gastrointestinal stromal tumors (GIST).

William R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the surgical barriers in treating patients with colorectal cancer that has metastasized outside of the liver.

Prudence Francis, MD, Peter MacCallum Cancer Centre, discusses the SOFT trial for patients with breast cancer.

Matthew H. Kulke, MD, Dana-Farber Cancer Institute, discusses the emerging data seen with cabozantinib (Cabometyx) for patients with neuroendocrine tumors (NETs).

Constantine S. Tam, MD, associate professor, Peter MacCallum Cancer Centre, discusses, the randomized phase III DUO trial of duvelisib versus ofatumumab (Arzerra) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Lecia V. Sequist, MD, associate professor of medicine, Harvard Medical School, Mary B. Saltonstall Chair, Oncology, Massachusetts General Hospital Center, discusses the tolerability of a new third-generation T790-specific inhibitor, osimertinib (Tagrisso).

Robert Ramirez, DO, FACP, Ochsner Medical Center, discusses treating patients with neuroendocrine tumors (NETs) of the lung.

Jamie Koprivnikar, MD, medical oncologist, John Theurer Cancer Center, discusses FLT3 inhibitors in the treatment of hematologic malignancies.

Steffi Oesterreich, PhD, professor and vice chair of Precision and Translational Pharmacology, University of Pittsburgh, discusses developing treatment for patients with invasive lobular carcinoma (ILC).

Dan J. Raz, MD, MAS, co-director, Lung Cancer and Thoracic Oncology Program, assistant professor, Division of Thoracic Surgery, Department of Surgery, City of Hope, discusses the subsets of the ALCHEMIST trial.

Jae Y. Kim, MD, chief, Division of Thoracic Surgery, Department of Surgery, assistant professor, Department of Surgery, City of Hope, discusses the use of immune checkpoint inhibitors in surgical patients with lung cancer.

Aditya Bardia, MD, MPH, assistant professor of medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses a trial investigating sacituzumab govitecan for patients with triple-negative breast cancer (TNBC).

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the abiraterone acetate (Zytiga) versus docetaxel for patients with prostate cancer.

Miguel-Angel Perales, MD, Deputy Chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, discusses determining which chimeric antigen receptor (CAR) T-cell therapy to use for patients with hematologic malignancies.

Erminia Massarelli, MD, PhD, MS, associate clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the adoption of alectinib (Alecensa) as the first-line therapy in the treatment of patients with ALK-positive non–small cell lung cancer (NSCLC).